Abstract
The disturbance of the dopaminergic neurotransmission is a key-feature in the neurobiology of schizophrenia. The interaction between the dopaminergic and the glutamatergic neurotransmission, however, attracted more notice to the glutamatergic system. Recent research focussed on factors influencing the glutamatergic neurotransmission. A pro-inflammatory immune state influences the glutamatergic neurotransmission indirectly by its effects on the tryptophan/kynurenine metabolism. The immune response in schizophrenia seems to be associated with the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and imbalance in the tryptophan/kynurenine metabolism resulting in increased production of kynurenic acid in the brain. This is associated with an imbalance in the glutamatergic neurotransmission, leading to an NMDA antagonism in schizophrenia. The immunological effects of antipsychotics reverse partly the immune imbalance and the unphysiologically enhanced production of the kynurenic acid. These immunological and neurochemical imbalances result in a chronic pro-inflammatory state in association with increased prostaglandin E2 (PGE2) production, increased cyclo-oxygenase-2 (COX-2) expression and increased pro-inflammatory cytokines production and NMDA receptor hypofunctioning. Substances acting directly on the kynurenine metabolism are still in very early stages of development, anti-inflammatory drugs acting indirectly on this metabolism are discussed as therapeutic or preventive agents in schizophrenia. Most of the existing data are related to COX-2 inhibitors, which have been tested in animal experiments and in clinical trials, pointing to favourable effects in schizophrenia.
Keywords: Schizophrenia, tryptophan, kynurenine, immune system psychoneuroimmunology
Current Pharmaceutical Design
Title: Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Volume: 17 Issue: 2
Author(s): Norbert Muller, Aye-Mu Myint and Markus J. Schwarz
Affiliation:
Keywords: Schizophrenia, tryptophan, kynurenine, immune system psychoneuroimmunology
Abstract: The disturbance of the dopaminergic neurotransmission is a key-feature in the neurobiology of schizophrenia. The interaction between the dopaminergic and the glutamatergic neurotransmission, however, attracted more notice to the glutamatergic system. Recent research focussed on factors influencing the glutamatergic neurotransmission. A pro-inflammatory immune state influences the glutamatergic neurotransmission indirectly by its effects on the tryptophan/kynurenine metabolism. The immune response in schizophrenia seems to be associated with the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and imbalance in the tryptophan/kynurenine metabolism resulting in increased production of kynurenic acid in the brain. This is associated with an imbalance in the glutamatergic neurotransmission, leading to an NMDA antagonism in schizophrenia. The immunological effects of antipsychotics reverse partly the immune imbalance and the unphysiologically enhanced production of the kynurenic acid. These immunological and neurochemical imbalances result in a chronic pro-inflammatory state in association with increased prostaglandin E2 (PGE2) production, increased cyclo-oxygenase-2 (COX-2) expression and increased pro-inflammatory cytokines production and NMDA receptor hypofunctioning. Substances acting directly on the kynurenine metabolism are still in very early stages of development, anti-inflammatory drugs acting indirectly on this metabolism are discussed as therapeutic or preventive agents in schizophrenia. Most of the existing data are related to COX-2 inhibitors, which have been tested in animal experiments and in clinical trials, pointing to favourable effects in schizophrenia.
Export Options
About this article
Cite this article as:
Muller Norbert, Myint Aye-Mu and J. Schwarz Markus, Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects, Current Pharmaceutical Design 2011; 17 (2) . https://dx.doi.org/10.2174/138161211795049552
DOI https://dx.doi.org/10.2174/138161211795049552 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels
Recent Patents on Anti-Infective Drug Discovery Infection and Anemia
Infectious Disorders - Drug Targets Synthesis and Mosquiticidal Activity of Novel Hydrazone Containing Pyrimidine Derivatives against Aedes aegypti
Letters in Drug Design & Discovery Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Current Perspective of COVID-19 on Neurology: A Mechanistic Insight
Combinatorial Chemistry & High Throughput Screening Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Molecular Mechanism of Aniline Induced Spleen Toxicity and Neuron Toxicity in Experimental Rat Exposure: A Review
Current Neuropharmacology Genetic Studies in Relation to Kuru: An Overview
Current Molecular Medicine β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design New Strategies for Immune-Mediated Anti-Viral Drug and Vaccine Development
Current Pharmaceutical Design The Role of Inflammation in Epilepsy
Current Pediatric Reviews